1. Home
  2. ICUI vs TNGX Comparison

ICUI vs TNGX Comparison

Compare ICUI & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ICU Medical Inc.

ICUI

ICU Medical Inc.

HOLD

Current Price

$165.97

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Logo Tango Therapeutics Inc.

TNGX

Tango Therapeutics Inc.

HOLD

Current Price

$22.01

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ICUI
TNGX
Founded
1984
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
4.1B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
ICUI
TNGX
Price
$165.97
$22.01
Analyst Decision
Buy
Strong Buy
Analyst Count
8
13
Target Price
★ $193.38
$47.09
AVG Volume (30 Days)
193.4K
★ 4.1M
Earning Date
11-05-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 100.62
26.89
EPS
★ 1.96
N/A
Revenue
★ $2,231,262,000.00
$62,384,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.44
N/A
P/E Ratio
$85.24
★ N/A
Revenue Growth
N/A
★ 48.29
52 Week Low
$113.37
$7.37
52 Week High
$192.85
$34.39

Technical Indicators

Market Signals
Indicator
ICUI
TNGX
Relative Strength Index (RSI) 55.69 44.55
Support Level $164.09 $20.46
Resistance Level $167.67 $25.68
Average True Range (ATR) 4.51 1.77
MACD 0.85 0.13
Stochastic Oscillator 86.13 18.07

Price Performance

Historical Comparison
ICUI
TNGX

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Share on Social Networks: